Immunogenic conjugates
OwnerPorter W. Andersoninventor
Life of this patent
Estimating the term…
Abstract
An immunogenic conjugate which is the reductive amination product of an immunogenic capsular polymer fragment having a reducing end and derived from a bacterial capsular polymer of a bacterial pathogen, and a bacterial toxin or toxoid. The invention also relates to methods for the preparation of the conjugates, a vaccine containing the conjugates which elicits effective levels of anti-capsular polymer antibodies in humans. Also disclosed are methods for inducing active immunization against systemic infection in young mammals caused by bacterial pathogens comprising the administration of an immunogenic amount of the above-described conjugate.
Claims50
immunogenic conjugate comprising the reductve amination product of an immunogenic capsular polymer fragment having a chain length of from about 10 to about 30 monomeric units and a reducing end, which fragment is derived from the capsular polymer of a Streptococcus pneumoniae or Haemophilus influenzae bacterium, and a bacterial toxin or toxoid.
An immunogenic conjugate comprising a formalin treated reductive amination product of an immunogenic capsular polymer fragment having a chain length of from about 10 to about 30 monomeric units and a reducing end, which fragment is derived from the capsular polymer of a Streptococcus pneumoniae or Haemophilus influenzae bacterium, and a bacterial toxin or toxoid.
An immunogenic conjugate of (1) a PRP polysaccharide fragment having reducing terminal groups derived from the capsular polysaccharide of Haemophilus influenzae type b by selective acidic hydrolysis of a portion of the ribosyl ribitol linkages therein and (2) the diphtheria toxin protein CRM.sub.197.
Dependencies are inferred from the claim text.